Liquidia Corporation (LQDA)
Liquidia Corporation Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - LQDA
NEW YORK, NY / ACCESSWIRE / August 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc. (LQDA) and Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK CITY, NY / ACCESSWIRE / August 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Liquidia Technologies, Inc. ("Liquidia" or "the Company") (NASDAQ:LQDA). Investors who purchased Liquidia securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LQDA.
Investors Are Invited To Partake In The Schall Law Firm's Inquiry Into Liquidia Corporation For Wrongful Practices
LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or "the Company") (NASDAQ:LQDA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Liquidia Corporation Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - LQDA
NEW YORK, NY / ACCESSWIRE / August 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
Liquidia Technologies, Inc. (LQDA) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Stockholders to Seek Compensation for Alleged Wrongdoings
NEW YORK CITY, NY / ACCESSWIRE / August 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Liquidia Technologies, Inc. ("Liquidia" or "the Company") (NASDAQ:LQDA). Investors who purchased Liquidia securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LQDA.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") LQDA. [email protected] The investigation concerns whether Liquidia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Liquidia Corporation Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - LQDA
NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
Shareholders That Lost Money on Liquidia Corporation (LQDA) Should Contact Levi & Korsinsky About Securities Fraud Investigation - LQDA
NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
Liquidia Corporation Is Being Investigated For Possible Securities Law Infractions And The Schall Law Firm Encourages Shareholders To Join
LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or "the Company") (NASDAQ:LQDA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LQDA STOCK ALERT: Levi & Korsinsky Notifies Liquidia Corporation Investors of an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
Liquidia Technologies, Inc. (LQDA) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
NEW YORK CITY, NY / ACCESSWIRE / August 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Liquidia Technologies, Inc. ("Liquidia" or "the Company") (NASDAQ:LQDA). Investors who purchased Liquidia securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LQDA.
Shareholders That Lost Money on Liquidia Corporation (LQDA) Should Contact Levi & Korsinsky About Securities Fraud Investigation - LQDA
NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
